Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

Advances in our understanding of early cystic fibrosis lung disease led by the Australian Early Surveillance Team for Cystic Fibrosis (AREST CF) have also indicated the potential utility of a number of biomarkers for monitoring disease severity.

Bile signalling promotes chronic respiratory infections and antibiotic tolerance

Bile signalling promotes chronic respiratory infections and antibiotic tolerance Despite aggressive antimicrobial therapy, many respiratory

Switch on the immune system early

Findings by Professor Pat Holt revealed researchers had been heading down the wrong path in their battle strategy against respiratory allergy and asthma.

Finding the cellular explanation for recurrent asthma exacerbations

This study is designed to identify the specific unique immune cell response that occurs in these children with recurrent disease.

Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma

This study demonstrates novel intrinsic differences in tight junctions gene and protein expression between airway epithelial cells of children with and without asthma

Tests offered

The Wal-yan Respiratory Research Centre offers a broad range of outpatient and portable tests for those affected by chronic respiratory conditions.

Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.

Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis. Abstract Although destructive airway

Treatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse model

Treatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model.

Novel end points for clinical trials in young children with cystic fibrosis

Cystic fibrosis (CF) lung disease commences early in the disease progression and is the most common cause of mortality.